检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《海南医学院学报》2009年第8期894-895,共2页Journal of Hainan Medical University
基 金:海南医学院科研基金资助学报项目(0020090091)~~
摘 要:目的:探讨托吡酯治疗Tourette综合征的临床效果及合适剂量。方法:本组79例Tourette综合征患儿均应用托吡酯单药治疗,起始剂量0.5mg·kg-1.d-1,滴定法加量,每周加量0.5mg·kg-1.d-1,最大剂量为3mg·kg-1.d-1,2次/d,用药3个月后依据抽动控制情况评定疗效,并观察药物不良反应。结果:79例中除2例出现明显药物不良反应而退出观察外,余77例于治疗后2~4周症状均获显著改善,抽动完全控制47例(61.03%),显效24例(31.16%),无效6例(7.79%),总有效率为92.19%。治疗早期3例出现疲乏,3例体重下降,2例出汗减少,继续用药后症状有所缓解,患儿均能耐受并逐渐缓解。结论:托吡酯治疗Tourette综合征疗效好,所需剂量小,不良反应轻,可作为治疗该病的首选药物之一。Objective: To determine the effect of low-dose topiramate on Tourette syndrome and its appropriate dosage. Methods: Seventy-nine children patients with Tourette syndrome were treated using topiramate solely, the initial dose was 0.5 mg ·kg^-1·d^-1, and the following dose of therapy was on the base of initial dose giving added dose of 0.5 mg·kg^-1·d^-1 weekly through titration, the maximal dose was 3 mg·kg^-1·d^-1, 2 times daily, the efficacy was evaluated after 3 months medication according to the improvement of tic, side effects of the drug were observed. Results: Two patients pulled out treatment due to markedly side effects of drug, symptoms of 77 patients improved significantly after 2 ~4 weeks therapy, tics disappeared in 47 eases (61.03%), effectual rate was 31.16 % (24 cases), 6 cases (7.79%) had no effect, total effective rate was 92.19%. Three eases happened fatigue in early time of therapy, 3 eases had weight loss, and 2 eases presented decreased sweating , these adverse reactions remitted in the following medication and they tolerated gradually. Conclusion: Topiramate has good efficacy on the treatment of Tourette syndrome and may be the primary choice of medication, with merits of small dosage and mild side effects.
关 键 词:TOURETTE综合征 托吡酯 疗效
分 类 号:R745.7[医药卫生—神经病学与精神病学] R977.7[医药卫生—临床医学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145